ACAD – acadia pharmaceuticals inc. (US:NASDAQ)
Stock Stats
News
ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at Wall St
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by analysts at Wall
Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Kihara James
Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Schneyer Mark C.
Form SCHEDULE 13G/A ACADIA PHARMACEUTICALS Filed by: RTW INVESTMENTS, LP
Form 4 ACADIA PHARMACEUTICALS For: Nov 10 Filed by: Daly James M
Form 144 ACADIA PHARMACEUTICALS Filed by: Daly James M
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.